Jubilant Biosys and Yale University have announced a research collaboration for multiple small molecule research programmes. Under the scope of this partnership, Jubilant Biosys will provide research services to investigators at Yale University working on novel therapeutic targets. Areas of collaboration include medicinal chemistry, structural biology, in-vitro and in-vivo pharmacology among others.

Commenting on this collaboration, Marcel Velterop, President Jubilant Biosys said "Yale is one of the top-ranked academic institutions in the US and we at Jubilant Biosys are delighted to be able to support scientific endeavours of investigators at Yale to pursue novel target ideas for unmet medical conditions. With our new discovery chemistry site scheduled to commence operations in 2021, we will further add to our capability a new infrastructure to service our partners."

"Our CRO relationships are an integral component in our pursuit of helping Yale's scientific community transition their research towards commercialisation, and we are pleased to have Jubilant Biosys join our entrepreneurial ecosystem," said Bill Wiesler, Director, New Ventures and Blavatnik Fund for Innovation at Yale, Office of Cooperative Research.